ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,260,825 | -36.3% | 291,927 | +22.1% | 0.00% | 0.0% |
| Q2 2023 | $5,116,077 | -45.0% | 239,069 | +3.9% | 0.00% | -50.0% |
| Q1 2023 | $9,304,839 | -15.0% | 230,090 | -2.3% | 0.00% | 0.0% |
| Q4 2022 | $10,952,948 | +20.9% | 235,446 | +34.9% | 0.00% | 0.0% |
| Q3 2022 | $9,056,000 | +38.5% | 174,595 | +26.2% | 0.00% | +100.0% |
| Q2 2022 | $6,540,000 | -8.6% | 138,356 | +37.7% | 0.00% | -50.0% |
| Q1 2022 | $7,153,000 | -20.1% | 100,501 | -16.0% | 0.00% | 0.0% |
| Q4 2021 | $8,947,000 | +53.9% | 119,651 | +16.9% | 0.00% | +100.0% |
| Q3 2021 | $5,814,000 | -7.9% | 102,332 | -28.7% | 0.00% | 0.0% |
| Q2 2021 | $6,313,000 | -5.8% | 143,431 | +5.5% | 0.00% | -50.0% |
| Q1 2021 | $6,704,000 | -1.3% | 135,929 | -15.8% | 0.00% | 0.0% |
| Q4 2020 | $6,795,000 | -55.9% | 161,414 | -52.1% | 0.00% | -50.0% |
| Q3 2020 | $15,425,000 | -15.5% | 336,926 | -7.4% | 0.00% | -33.3% |
| Q2 2020 | $18,264,000 | -4.0% | 363,748 | -1.6% | 0.01% | -14.3% |
| Q1 2020 | $19,019,000 | -8.1% | 369,821 | +10.4% | 0.01% | +40.0% |
| Q4 2019 | $20,686,000 | +26.0% | 334,833 | +22.5% | 0.01% | 0.0% |
| Q3 2019 | $16,421,000 | +10.2% | 273,324 | +54.8% | 0.01% | +25.0% |
| Q2 2019 | $14,896,000 | +8.2% | 176,537 | +22.5% | 0.00% | 0.0% |
| Q1 2019 | $13,761,000 | -11.4% | 144,064 | -34.3% | 0.00% | -20.0% |
| Q4 2018 | $15,528,000 | +15.3% | 219,237 | +39.1% | 0.01% | +66.7% |
| Q3 2018 | $13,468,000 | -3.7% | 157,599 | +30.6% | 0.00% | -25.0% |
| Q2 2018 | $13,989,000 | +8.6% | 120,695 | -24.2% | 0.00% | +33.3% |
| Q1 2018 | $12,881,000 | +99.0% | 159,208 | +44.3% | 0.00% | +50.0% |
| Q4 2017 | $6,472,000 | +64.6% | 110,304 | +31.3% | 0.00% | +100.0% |
| Q3 2017 | $3,933,000 | +30.6% | 84,035 | +0.4% | 0.00% | 0.0% |
| Q2 2017 | $3,012,000 | +67.1% | 83,704 | +43.0% | 0.00% | – |
| Q1 2017 | $1,803,000 | -34.7% | 58,550 | -28.9% | 0.00% | -100.0% |
| Q4 2016 | $2,759,000 | +389.2% | 82,349 | +288.2% | 0.00% | – |
| Q3 2016 | $564,000 | +142.1% | 21,213 | +167.7% | 0.00% | – |
| Q1 2016 | $233,000 | -64.0% | 7,923 | -59.6% | 0.00% | – |
| Q4 2015 | $647,000 | -53.7% | 19,591 | -36.9% | 0.00% | – |
| Q2 2015 | $1,397,000 | +2.5% | 31,059 | -30.2% | 0.00% | – |
| Q1 2015 | $1,363,000 | -80.1% | 44,497 | -67.0% | 0.00% | -100.0% |
| Q4 2014 | $6,866,000 | +265.6% | 135,031 | +184.5% | 0.00% | +100.0% |
| Q3 2014 | $1,878,000 | +773.5% | 47,467 | +849.5% | 0.00% | – |
| Q2 2014 | $215,000 | -17.3% | 4,999 | -47.6% | 0.00% | – |
| Q4 2013 | $260,000 | +18.2% | 9,541 | -0.4% | 0.00% | – |
| Q3 2013 | $220,000 | -9.1% | 9,581 | -29.9% | 0.00% | – |
| Q2 2013 | $242,000 | – | 13,674 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |